Galmed updates shareholder articles of association

Q: What did Galmed Pharmaceuticals (GLMD) shareholders approve at the August 2025 meeting?

Shareholders of Galmed Pharmaceuticals Ltd. approved an amended and restated set of articles of association at a Special General Meeting held on August 15, 2025.

Q: When was the Galmed Pharmaceuticals (GLMD) Special General Meeting held?

The Special General Meeting of Galmed Pharmaceuticals Ltd. shareholders was held on August 15, 2025.

Q: Under what legal framework was the Galmed (GLMD) proposal approved?

The proposal to amend and restate Galmed’s articles of association was approved with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.

Q: Where can investors find the amended articles of association of Galmed (GLMD)?

The amended and restated articles of association of Galmed Pharmaceuticals Ltd. are attached as Exhibit 99.1 to this report.

Q: How does this Galmed (GLMD) Form 6-K relate to existing registration statements?

This Form 6-K is incorporated by reference into Galmed’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163) and Form F-3 (Nos. 333-272722, 333-283241).

Galmed Pharmaceuticals Ltd. reports that its shareholders approved an amended and restated set of articles of association at a Special General Meeting held on August 15, 2025.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Galmed Pharmaceuticals Ltd. reports that its shareholders approved an amended and restated set of articles of association at a Special General Meeting held on August 15, 2025. The proposal was described in a previously distributed proxy statement and was approved with the requisite majority under Israeli Companies Law. The updated articles of association are provided as an exhibit and this report is incorporated by reference into Galmed’s existing Form S-8 and Form F-3 registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Galmed Pharmaceuticals (GLMD) shareholders approve at the August 2025 meeting?

Shareholders of Galmed Pharmaceuticals Ltd. approved an amended and restated set of articles of association at a Special General Meeting held on August 15, 2025.

When was the Galmed Pharmaceuticals (GLMD) Special General Meeting held?

The Special General Meeting of Galmed Pharmaceuticals Ltd. shareholders was held on August 15, 2025.

Under what legal framework was the Galmed (GLMD) proposal approved?

The proposal to amend and restate Galmed’s articles of association was approved with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.

Where can investors find the amended articles of association of Galmed (GLMD)?

The amended and restated articles of association of Galmed Pharmaceuticals Ltd. are attached as Exhibit 99.1 to this report.

How does this Galmed (GLMD) Form 6-K relate to existing registration statements?

This Form 6-K is incorporated by reference into Galmed’s Registration Statements on Form S-8 (Nos. 333-206292, 333-227441, 333-284163) and Form F-3 (Nos. 333-272722, 333-283241).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 08/15/2025 - 04:05 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of August 2025

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

c/o Meitar Law Offices Abba Hillel Silver Rd.,

Ramat Gan, 5250608

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On August 15, 2025, Galmed Pharmaceuticals Ltd. (the “Company”) held a Special General Meeting of Shareholders (the “Meeting”). At the Meeting, the Company’s shareholders voted on the proposal described in the proxy statement for the Meeting included as an exhibit to the Company’s report on Form 6-K furnished by the Company with the Securities and Exchange Commission on July 24, 2025. The proposal brought before the shareholders at the Meeting was approved by the shareholders of the Company with the requisite majority in accordance with the Israeli Companies Law, 5759-1999.

A copy of the Company’s amended and restated articles of association, approved by shareholders at the Meeting, is attached hereto as Exhibit 99.1.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration Nos. 333-206292, 333-227441, and 333-284163) and the Company’s Registration Statement on Form F-3 (Registration Nos. 333-272722 and 333-283241).

EXHIBIT INDEX

Exhibit No.		Description

99.1		Amended and Restated Articles of Association

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Galmed Pharmaceuticals Ltd.

Date: August 15, 2025	By:	/s/ Allen Baharaff
		Allen Baharaff
		President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR